StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.37−0.01 (-3.62%)

Close on Nov 18, 2026Market cap $7.20MP/E –Yield –

Ensysce Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ensysce Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$12.66M. For fiscal 2025 it was -$10.24M. The highest annual figure on record is -$959.24K in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.24M–
FY2024Dec 31, 2024-$6.73M–
FY2023Dec 31, 2023-$10.72M–
FY2022Dec 31, 2022-$24.22M–
FY2021Dec 31, 2021-$19.87M–
FY2020Dec 31, 2020-$1.61M–
FY2019Dec 31, 2019-$3.33M–
FY2018Dec 31, 2018-$959.24K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.58M–
Q1 FY2026Mar 31, 2026-$3.56M–
Q4 FY2025Dec 31, 2025-$2.78M–
Q3 FY2025Sep 30, 2025-$3.74M-680.2%
Q2 FY2025Jun 30, 2025-$1.75M–
Q1 FY2025Mar 31, 2025-$1.97M–
Q4 FY2024Dec 31, 2024-$3.58M–
Q3 FY2024Sep 30, 2024$644.75K–
Q2 FY2024Jun 30, 2024-$1.96M–
Q1 FY2024Mar 31, 2024-$1.84M–
Q4 FY2023Dec 31, 2023-$3.16M–
Q3 FY2023Sep 30, 2023-$2.71M–
Q2 FY2023Jun 30, 2023-$2.29M–
Q1 FY2023Mar 31, 2023-$2.56M–
Q4 FY2022Dec 31, 2022-$6.20M–
Q3 FY2022Sep 30, 2022-$6.16M–
Q2 FY2022Jun 30, 2022-$7.06M–
Q1 FY2022Mar 31, 2022-$4.80M–
Q4 FY2021Dec 31, 2021-$2.01M–
Q3 FY2021Sep 30, 2021-$16.89M–
Q2 FY2021Jun 30, 2021-$412.62K-396.7%
Q1 FY2021Mar 31, 2021-$524.27K–
Q4 FY2020Dec 31, 2020-$1.09M–
Q3 FY2020Sep 30, 2020-$404.77K–
Q2 FY2020Jun 30, 2020$139.08K–
Q1 FY2020Mar 31, 2020-$915.18K–
Q4 FY2019Dec 31, 2019-$1.93M–
Q3 FY2019Sep 30, 2019-$584.42K–
Q2 FY2019Jun 30, 2019-$625.94K–
Q1 FY2019Mar 31, 2019-$189.17K–
Q4 FY2018Dec 31, 2018-$229.38K–
Q3 FY2018Sep 30, 2018-$248.19K–
Q2 FY2018Jun 30, 2018-$311.54K–
Q1 FY2018Mar 31, 2018-$170.13K–

More Ensysce Biosciences figures

See a number that looks wrong?